Under which circumstances these cross-reactive CD4+ T cells are primed remains unclear but their frequent HLA-DRB1*1501 restriction would explain additive MS risk due to HLA-DRB1*1501 expression and EBV infection. Here, CD4 is linked to myeloid sarcoma.